Metabolic inhibitors have been used in oncology for decades, dating back to antimetabolites
developed in the 1940s. In the past 25 years, there has been increased recognition of …

The delivery of a drug to a specific organ or tissue at an efficacious concentration is the
pharmacokinetic (PK) hallmark of promoting effective pharmacological action at a target site …

Alzheimer's disease (AD) is a neurodegenerative condition in which clinical symptoms are
highly correlated with the loss of glutamatergic synapses. While later stages of AD are …

Epileptogenic seizures, or status epilepticus (SE), leads to excitotoxic injury in hippocampal
and limbic neurons in the kainic acid (KA) animal model of temporal lobe epilepsy (TLE) …

Simple Summary Melanoma is a very aggressive and fatal malignant tumor. While curable if
diagnosed in its early stages, advanced melanoma, despite the complex therapeutic …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects the first
and second motoneurons (MNs), associated with muscle weakness, paralysis and finally …

Phosphate and amino acid prodrugs of the HIV-1 protease inhibitor (PI) atazanavir (1) were
prepared and evaluated to address solubility and absorption limitations. While the …

Parthenolide (PTL) can target NLRP3 inflammasome to treat inflammation and its related
disease, but its cytotoxicity limits further development as an anti-inflammatory drug. A series …

Riluzole, approved to manage amyotrophic lateral sclerosis, is mechanistically unique
among glutamate-based therapeutics because it reduces glutamate transmission through a …

Brusatol, a quassinoid natural product, is effective against multiple diseases including
hematologic malignancies, as we reported recently by targeting the PI3Kγ isoform, but …